The future role of anti-tumour necrosis factor-α products in the treatment of Crohn's disease (vol 56, pg 299, 1998)

被引：0
作者：
van Hogezand, RA
Verspaget, HW
机构：
来源：
DRUGS | 1999年 / 57卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [31] Amaurosis in patients with giant cell arteritis:: treatment with anti-tumour necrosis factor-α
    Torrente, S. V.
    Gueerri, R. C.
    Perez-Garcia, C.
    Benito, P.
    Carbonell, J.
    INTERNAL MEDICINE JOURNAL, 2007, 37 (04) : 280 - U7
  • [32] Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease
    Mattoo, Vandita Y.
    Basnayake, Chamara
    Connell, William R.
    Ding, Nik
    Kamm, Michael A.
    Lust, Mark
    Niewiadomski, Ola
    Thompson, Alexander
    Wright, Emily K.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (03) : 249 - 266
  • [33] The level of intestinal inflammation and fibrosis in resection specimens after preoperative anti-tumour necrosis factor-α treatment in patients with Crohn's disease: a comparative pilot study
    Torle, J.
    Dabir, P.
    Korsgaard, U.
    Christiansen, J. J.
    Qvist, N.
    El-Hussuna, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S357 - S358
  • [34] The use of a novel anti-tumour necrosis factor α (Infliximab, Remicade™).: A new strategy for medical treatment of Crohn's disease -: Foreword
    Campieri, M
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 31 (06): : 502 - 502
  • [35] Severe cardiomyopathy following treatment with the tumour necrosis factor-α inhibitor adalimumab for Crohn's disease
    Emmert, Maximilian Y.
    Salzberg, Sacha P.
    Emmert, Lorenz S.
    Behjati, Sohil
    Plass, Andre
    Felix, Christian
    Falk, Volkmar
    Gruenenfelder, Juerg
    EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (11) : 1106 - 1109
  • [36] AUDIT OF ANTI-TUMOUR NECROSIS FACTOR THERAPY IN CROHN'S DISEASE: BETTER RESULTS IN PATIENTS WITH NO PREVIOUS SURGERY
    Patel, R. N.
    Gregg, B.
    Kneebone, A.
    Leiper, K. P.
    Ellis, A.
    Watson, A. J.
    Rhodes, J. M.
    GUT, 2009, 58 : A99 - A100
  • [37] Tumour necrosis factor-α antagonists and their therapeutic applications (vol 8, pg 1307, 1998)
    Lowe, C
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (11) : 1565 - 1565
  • [38] Letter: limitations of studies to evaluate the significance of anti-tumour necrosis factor serum levels in Crohn's disease
    Chaparro, M.
    Gisbert, J. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (01) : 120 - 121
  • [39] Antibodies to tumour necrosis factor α as treatment for Crohn's disease
    Bell, S
    Kamm, MA
    LANCET, 2000, 355 (9207) : 858 - 860
  • [40] The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
    Alric, Hadrien
    Amiot, Aurelien
    Kirchgesner, Julien
    Treton, Xavier
    Allez, Mathieu
    Bouhnik, Yoram
    Beaugerie, Laurent
    Carbonnel, Franck
    Meyer, Antoine
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (10) : 948 - 957
12345